Health
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
PRINCETON, N.J., June 11, 2025--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu...
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/88f783f368dca5ae112a3fbc35b28531"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4jZyntQh_vX3Y2dxYDhj7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/88f783f368dca5ae112a3fbc35b28531","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0.lWHXi0I0IMX2mqGgyv7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/88f783f368dca5ae112a3fbc35b28531","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, measures of disease activity and quality of life at Week 16 in POETYK PsA-1","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"New data from POETYK PsA-2 trial demonstrated that meaningful clinical responses continued to improve and outcomes were maintained through Week 52","length":146,"tagName":"p","attribs":{}},{"type":"text","content":"Sotyktu demonstrated safety consistent with the established clinical profile and was well tolerated in both studies, with no new safety signals","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., June 11, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive data from the pivotal Phase 3 POETYK PsA-1 trial (IM011-054) evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD). The trial met its primary endpoint, with a significantly greater proportion of patients treated with Sotyktu achieving ACR20 response (at least a 20 percent improvement in signs and symptoms of disease) compared with placebo at Week 16 (54.2% versus 34.1%, respectively; p<0.0001). The safety profile of Sotyktu through 16 weeks of treatment was consistent with what has been reported throughout the clinical trial programs for Sotyktu, including the Phase 3 POETYK PsA-2 trial and the Phase 3 moderate-to-severe plaque psoriasis (PsO) clinical trials.","length":929,"tagName":"p...